To explore the efficacy of Iparomlimab and Tuvonralimab (QL1706) in combination with SOX chemotherapy versus chemotherapy alone for the neoadjuvant treatment of locally-progressed gastric/gastroesophageal union adenocarcinomas by evaluating the complete pathologic remission rate (pCR).
Voluntary participation in the study and signing of informed consent;
Age ≥18 years and ≤75 years;
Pathologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma;
Clinical staging of T3N+ or T4a any N, M0 (according to AJCC 8th edition staging), with potential radical resection confirmed by CT or MRI;
Known HER2 positivity;
Known peritoneal metastases or positive peritoneal cytology (CY1P0) or T4b (according to AJCC 8th edition);
Presence of unresectable factors including unresectable tumors, contraindications to surgery and refusal of surgery;
The presence of a pre-existing or concurrent malignancy, with the exception of cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and carcinoma in situ of the breast